^
Association details:
Biomarker:No biomarker
Cancer:Prostate Cancer
Drug:abiraterone acetate (CYP17A1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
05/09/2011
Excerpt:
Zytiga is indicated with prednisone or prednisolone for:...the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated...the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
Secondary therapy:
prednisolone; prednisone
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with...metastatic castration-resistant prostate cancer (CRPC)….metastatic high-risk castration-sensitive prostate cancer (CSPC).
Secondary therapy:
prednisone
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Prostate Cancer: SYSTEMIC THERAPY FOR M1 CRPC: ADENOCARCINOMA...No prior docetaxel/no prior novel hormone therapy...Preferred regimens...Abiraterone…Abiraterone should be given with concurrent steroid...Prednisone 5 mg orally once daily for the standard formulation...Methylprednisolone 4 mg orally twice daily for the fine-particle formulation (category 2B).
Secondary therapy:
methylprednisolone acetate; prednisone
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
...the NCCN panel to recommend abiraterone with 5-mg once-daily prednisone as a treatment option with ADT for men with newly diagnosed, M1, castration-naive prostrate cancer...Prostate Cancer: SYSTEMIC THERAPY FOR M1 CRPC: ADENOCARCINOMA...Prior novel hormone therapy/No prior docetaxel...Other recommended regimens...Abiraterone + dexamethasone
Secondary therapy:
prednisone; dexamethasone
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Excerpt:
...abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy.
Secondary therapy:
prednisone
DOI:
10.1056/NEJMoa1014618
Trial ID: